|1.||Schmidt, J: 2 articles (12/2002 - 01/2000)|
|2.||Shal'nova, S A: 2 articles (01/2000 - 01/2000)|
|3.||Kutishenko, N P: 2 articles (01/2000 - 01/2000)|
|4.||Koniakhina, I P: 2 articles (01/2000 - 01/2000)|
|5.||Alimova, E V: 2 articles (01/2000 - 01/2000)|
|6.||Semenova, Iu E: 2 articles (01/2000 - 01/2000)|
|7.||Deev, A D: 2 articles (01/2000 - 01/2000)|
|8.||Martsevich, S Iu: 2 articles (01/2000 - 01/2000)|
|9.||Fernández, José R: 1 article (05/2010)|
|10.||Ayala, Diana E: 1 article (05/2010)|
|1.||Hypertension (High Blood Pressure)
08/01/1999 - "Thus spirapril is seen to be an effective and well-tolerated antihypertensive drug whose efficacy is clearly related to baseline blood pressure and thus is also very effective in the treatment of severe forms of hypertension."
01/01/1994 - "In conclusion, the studied dosages of spirapril were equally effective in reducing DBP, and the overall good decrease in blood pressure at the end of the dosing interval indicates that once-daily administration is effective in patients with mild-to-moderate hypertension."
01/01/2000 - "6 mg daily dose of quadropril is an effective and safe therapy for arterial hypertension."
01/01/1994 - "This was a multicentre randomized, double-blind, parallel-group study to compare the antihypertensive efficacy of spirapril at 3 mg with 12 mg once daily, as determined by 24-hour ambulatory blood pressure monitoring (ABPM), in patients with mild to severe essential hypertension. "
08/01/1999 - "The efficacy and tolerability of spirapril were evaluated in a prospective, multicentre, post-marketing surveillance study on the treatment of arterial hypertension in 5000 patients, most of whom had received a single daily dose of 6 mg spirapril. "
06/01/1997 - "The results of the second year of erxtension indicate that spirapril is a very effective and safe ACE-inhibitor which will extend in a significant way therapeutic means in patients with chronic heart failure."
06/01/1997 - "The CASSIS study was a double-blind multicentric controlled Czech and Slovak study focused on treatment of chronic heart failure with the ACE inhibitor spirapril; it was conducted for 12 weeks. "
06/01/1997 - "[Therapy of heart failure with spirapril--the open phase of the CASSIS study. "
06/01/1997 - "Spirapril, an ACE-inhibitor without the SH group was tested in a randomized double-blind multicentric study in patients with chronic symptomatic heart failure (NYHA II-IV). "
01/01/1996 - "Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure."
|3.||Chronic Kidney Failure (Chronic Renal Failure)
08/15/1994 - "[Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril]."
01/01/1994 - "Spirapril in chronic renal failure."
08/01/1999 - "ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril."
08/15/1994 - "Spirapril 6 mg once daily is concluded to be a well tolerated antihypertensive therapy for patients with mild to moderate hypertension and varying degrees of chronic renal failure."
01/01/1994 - "Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure."
|4.||Chronic Renal Insufficiency
02/01/1999 - "Thus, (a) treatment with spirapril in patients with mild to moderate chronic renal insufficiency was not associated with deleterious effects on kidney function; (b) spirapril in a dose of 6 mg alone or in combination with 5 mg isradipine is effective in reducing blood pressure in hypertensive patients with reduced kidney function."
|5.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
12/05/2002 - "[Influence of ACE inhibitor spirapril on left ventricular hypertrophy]."
01/01/1994 - "Regression of left ventricular hypertrophy by spirapril."
01/01/1994 - "To assess the long-term course of regression of left ventricular hypertrophy (LVH) and haemodynamic changes during spirapril treatment, 11 male hypertensive patients with a left ventricular mass (LVM) > 240 g and a mean age of 48 (range 41-60) years were followed-up with echo-Doppler examinations for 36 months. "
03/01/1993 - "Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats."
03/01/1992 - "Effect of spirapril on left ventricular hypertrophy due to volume overload in rats."
|6.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)